Compare Dell Technologies Inc (DELL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Dell Technologies Inc trades at $448.46 (market cap $295.86B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Dell Technologies Inc is far larger — about 2.2× Vertex Pharmaceuticals Incorporated's market cap, and Dell Technologies Inc pays a 0.55% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| DELL | VRTX | |
|---|---|---|
Market Cap | $295.86B | $132.79B |
Sector | Technology | Health |
52-Week High | $467.27 | $529.65 |
52-Week Low | $111.10 | $376.62 |
Enterprise Value | $315.44B | $126.92B |
Dividend Yield | 0.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies stock trades at $453.78, up 3.69% in the last 24 hours, reflecting strong momentum driven by AI server demand and consistent earnings beats. The technical outlook is bullish with support at $428 and resistance at $467. Recent quarterly EPS results exceeded expectations, with Q1 2026 actual EPS of $4.86 beating the $2.96 estimate, signaling robust operational performance. Revenue for 2025 reached $95.57 billion, with a net income margin of 6.28%, while analyst consensus leans bullish with a $503.76 price target.
The outlook for Dell is positive, supported by growth in AI infrastructure and a solid financial trajectory, but risks include competitive pressures and reliance on tech spending cycles. Investment opportunities center on expanding profit margins and market share in servers, though investors should monitor debt levels and macroeconomic factors that could impact stock volatility.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
